Siemens Shareholders to Vote on Healthineers Spin-Off in 2027

Siemens stock rose over 3% after announcing a 2027 shareholder vote to spin off 30% of Siemens Healthineers, clarifying its corporate restructuring timeline.

Siemens shares surged over 3% on Friday, closing at €247.65, as the industrial giant finally provided a concrete timeline for its long-anticipated corporate restructuring. The company announced it will ask shareholders to vote on the direct spin-off of a further 30% stake in Siemens Healthineers at its Annual General Meeting in February 2027.

This move clarifies a strategic direction first signaled in November 2025, offering investors the planning certainty they had demanded. Under the German Transformation Act, Siemens shareholders would receive Healthineers shares directly credited to their deposit accounts. The transaction would reduce Siemens's current 67% majority stake, relegating Healthineers to a financial holding and allowing the parent company to focus capital on its core industrial automation, smart infrastructure, and mobility businesses.

While the strategic rationale is clear, the pace of the separation has drawn mixed reactions. Analysts at RBC Capital Markets maintained their 'Sector Perform' rating with a €270 price target. Analyst Mark Fielding acknowledged the transaction's strategic value but suggested the timeline could disappoint shorter-term investors. In contrast, Goldman Sachs has a 'Buy' rating on Siemens, forecasting earnings per share of €10.97 for 2026.

A significant unresolved issue is the tax neutrality of the transaction for shareholders. Siemens describes the clarification process with financial authorities as "well advanced," but the final regulatory green light is still pending, leaving the entire schedule provisional.

The market reaction highlighted a divergence between the parent and its subsidiary. While Siemens stock climbed, Healthineers shares dipped 0.26% to €38.37 on Friday, pressured by a price target cut from Morgan Stanley, which lowered its objective from €44 to €41. Year-to-date, Healthineers has declined nearly 14%, reflecting investor scrutiny of its prospects as a fully independent listed company.

From a technical perspective, Siemens's recent rally is showing strength. The stock has reclaimed positions above its 50, 100, and 200-day moving averages, a pattern UBS views as positive for further gains. The next key resistance level is seen around the psychologically important €250 mark, while support lies near €231, where the moving averages converge. The share price remains roughly 5% below its 52-week high of €261.55.

Investor attention now shifts to the upcoming quarterly report on May 13, which will cover the second quarter of fiscal 2026. Margins in the Digital Industries and Smart Infrastructure segments will be under particular scrutiny, serving as an early stress test for the stock's recovery rally, which has seen it gain approximately 32% since its April low. Until the 2027 vote, the operational performance of these core industrial divisions will be the primary driver for Siemens's equity.